Edward Weber, MD

Edward Weber, MD

Seattle, Washington

Edward Weber, MD, is a retired medical oncologist living in Seattle, Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, Dr. Weber attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington.

A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then pursued a fellowship in hematology and oncology at the University of Washington.

His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.

Toward the end of his career, he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002, he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.

Talks by Edward Weber, MD

PCa Commentary | Volume 198 – February 2025

Pluvicto was approved in March 2022 for therapy in men with heavily pretreated castration resistant metastatic prostate cancer, and since then, it has become a frequently prescribed life-prolonging treatment. Sartor et al., NEJM 2021, reported that the median imaging-based progression-free survival for 177Lu PSMA was 8.7 months vs. 3.4 for ADT alone, and the median overall survival was 15.3 months vs.11.3 for ADT. Quality of life was similar. Pluvicto is administered via a short IV infusion every 6 weeks for 4-6 cycles.

Read More